MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2016 International Congress

    Defective ubiquitinated mitochondria accumulation in aged Parkinsonian LRRK2R1441G knockin mice

    H.F. Liu, P.W.L. Ho, L.F. Li, G.C.T. Leung, C.S.C. Lam, M.H.W. Kung, D.B. Ramsden, S.L. Ho (Hong Kong, Hong Kong)

    Objective: (1) To determine potential accumulation of defective ubiquitinated mitochondria in the brains of aged LRRK2R1441G knockin (KI) mice and their age-matched wildtype controls; and…
  • 2016 International Congress

    Differential expression of cerebral dopamine neurotrophic factor (CDNF) in the hippocampus and in the striatum of LRRK-2 mutant rat model of Parkinson’s disease

    J. Varghese, K. Terpstra, S. Chiu, R. Mishra, Y. Bureau (London, ON, Canada)

    Objective: The objective of our study was to characterize the behavioral phenotype of the transgenic LRRK-2 rat in the context of PD model and to…
  • 2016 International Congress

    Detection of leucine-rich repeat kinase 2 in human biofluids

    E. Mutez, W. Sibran, T. Comptdaer, P. Semaille, M. Drouyer, S. Bleuse, L. Defebvre, A. Destee, M.C. Chartier-Harlin, J.M. Taymans (Lille, France)

    Objective: To evaluate the presence of leucine-rich repeat kinase 2 (LRRK2) in human biosamples, including cerebrospinal fluid (CSF) and urine, as a first step towards…
  • 2016 International Congress

    A cognitive fMRI study of non-manifesting LRRK2 and GBA carriers

    A. Thaler, N. Bregman, A. Mirelman, T. Gurevich, M. Gana-Weiss, A. Orr-Urtreger, T. Hendler, N. Giladi (Tel-Aviv, Israel)

    Objective: To assess the cognitive profile of non-manifesting carriers of GBA and LRRK2 mutations using two fMRI tasks: a Stroop interference and N-Back working memory…
  • 2016 International Congress

    Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity

    C.H. Lin, H.I. Lin, M.L. Chen, T.T. Lai, L.P. Cao, M.J. Farrer, R.M. Wu, C.T. Chien (Taipei, Taiwan)

    Objective: To identify disease-modifying therapy for LRRK2-G2019S parkinsonism. Background: Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson's disease (PD) without…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #29509 (loading title)
  • Expanding the Phenotype of KCNA2 Mutation: Tics and Stereotypies
  • #22661 (not found)
  • #29591 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley